Designed for trade association, exhibitors, academic institutions and speakers, List and promote your online events
Largest database of verified shows since 2015, Detailed profiles of verified trade shows, conferences and consumer shows. Create your event and attract attendees and exhibitiors, Listing tools for verification, institution and corporation.
Connect with verified event organizers, Listing and RFP tools for verified venue operators.Size events by verified attendee and exhibitor count database
Research verified b2b events by industry and profession, Review virtual exhibitor showcase. Create Profile. Connect with verified event organizers and exhibitors.
Search 900k verified exhibitor database organizedby 2,000+ events since 2018.
Professor of Biochemistry at University of Washington
Towards Next Generation de novo Designed Protein Therapeutics
This presentation will describe recent advances in de novo protein design, and the application of these advances to new therapeutic and vaccine modalities.
Shing-Yiu Yip and Cecilia M. Hepp Associate Professor of Dermatology at Harvard Medical School
TCR Sequencing: Transforming the Diagnosis and Care of Cutaneous T cell Lymphomas
Cutaneous T cell lymphomas are a heterogeneous collection of non-Hodgkin’s lymphomas that arise from T cells tropic for the skin. High throughput TCR sequencing (HTS) is transforming the care of patients with these cancers. HTS provides rapid and accurate diagnoses, allows direct measurement of malignant T cells in skin before and after therapeutic interventions and discriminates patients with indolent lymphomas from those that will develop progressive, often lethal disease.
President and Executive Vice President at Medimmune and AstraZeneca
Benralizumab, A Monoclonal Antibody Engineered for Enhanced NK-cell Mediated Eosinophil Depletion
Eosinophilia in patients with asthma correlates with increased exacerbation susceptibility. Benralizumab is a humanized, monoclonal antibody that targets the IL-5 receptor alpha antigen on eosinophils. Afucosylation of benralizumab enhances antibody-dependent cell-mediated cytotoxicity activity resulting in potent and rapid depletion of eosinophils. Benralizumab has demonstrated clinical efficacy in two pivotal Phase III trials, resulting in reductions of asthma exacerbations.
